Systematic review with meta‐analysis: Diagnostic performance of faecal calprotectin in distinguishing inflammatory bowel disease from irritable bowel syndrome in adults
Alimentary Pharmacology & Therapeutics · 2023-12 · 58 (11-12) · 1120-1131
DOI: 10.1111/apt.17754 ↗At a glance
Metaanalyse in Alimentary Pharmacology & Therapeutics, published online on 2023-10-12. Written by Elton Dajti and 12 co-authors. Institution: Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy. Major MEDLINE topics: Inflammatory Bowel Diseases, Irritable Bowel Syndrome. Cited 46 times so far (Crossref); 40 references. The full text is freely available (open access, CC BY-NC 4.0).
Abstract (original language)
Background
Symptoms of inflammatory bowel disease (IBD) often overlap with those of irritable bowel syndrome (IBS).
Aim
To evaluate the diagnostic performance of faecal calprotectin in distinguishing patients with IBD from those with IBS Methods We searched MEDLINE, Embase, Scopus, and Cochrane Library databases up to 1 January 2023. Studies were included if they assessed the diagnostic performance of faecal calprotectin in distinguishing IBD from IBS (defined according to the Rome criteria) using colonoscopy with histology or radiology as reference standard in adults. We calculated summary sensitivity and specificity and their 95% confidence intervals (CI) using a random‐effect bivariate model. The risk of bias was assessed using the Quality Assessment of Diagnostic Accuracy Studies II.
Results
We included 17 studies with a total of 1956 patients. The summary sensitivity was 85.8% (95% CI: 78.3–91), and the specificity was 91.7% (95% CI: 84.5–95.7). At a prevalence of IBD of 1%, the negative predictive value was 99.8%, while the positive predictive value was only 9%. Subgroup analyses showed a higher sensitivity in Western than in Eastern countries (88% vs 73%) and at a cut‐off of ≤50 μg/g than at >50 μg/g (87% vs. 79%), with similar estimates of specificity. All studies were at “high” or “unclear” risk of bias.
Conclusions
Faecal calprotectin is a reliable test in distinguishing patients with IBD from those with IBS. Faecal calprotectin seems to have a better sensitivity in Western countries and at a cut‐off of ≤50 μg/g.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
- Gastroenterology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, S. Orsola Hospital, Bologna, Italy.
- Gastro-Esophageal Disease Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, S. Orsola Hospital, Bologna, Italy.
- Gastroenterology Unit, Hospital of Imola, Imola, Italy.
- IBD Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, S. Orsola Hospital, Bologna, Italy.
ORCID profiles: Elton Dajti, Leonardo Frazzoni, Carlo Calabrese, Rocco Maurizio Zagari
Cite
APA
Dajti, E., Frazzoni, L., Iascone, V., Secco, M., Vestito, A., Fuccio, L., Eusebi, L. H., Fusaroli, P., Rizzello, F., Calabrese, C., Gionchetti, P., Bazzoli, F., & Zagari, R. M. (2023). Systematic review with meta‐analysis: Diagnostic performance of faecal calprotectin in distinguishing inflammatory bowel disease from irritable bowel syndrome in adults. Alimentary Pharmacology & Therapeutics, 58(11-12), 1120-1131. https://doi.org/10.1111/apt.17754
Vancouver
Dajti E, Frazzoni L, Iascone V, Secco M, Vestito A, Fuccio L, et al. Systematic review with meta‐analysis: Diagnostic performance of faecal calprotectin in distinguishing inflammatory bowel disease from irritable bowel syndrome in adults. Alimentary Pharmacology & Therapeutics. 2023;58(11-12):1120-1131. doi:10.1111/apt.17754
BibTeX
@article{Dajti2023,
author = {Dajti, Elton and Frazzoni, Leonardo and Iascone, Veronica and Secco, Matteo and Vestito, Amanda and Fuccio, Lorenzo and Eusebi, Leonardo Henry and Fusaroli, Pietro and Rizzello, Fernando and Calabrese, Carlo and Gionchetti, Paolo and Bazzoli, Franco and Zagari, Rocco Maurizio},
title = {Systematic review with meta‐analysis: Diagnostic performance of faecal calprotectin in distinguishing inflammatory bowel disease from irritable bowel syndrome in adults},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2023},
volume = {58},
number = {11-12},
pages = {1120--1131},
doi = {10.1111/apt.17754}
}
EUVIMED